Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

20190219_EGA_MelanomaOnTreatment - samples

ABSTRACT: Illumina platform sequencing data for matched tumour-normal DNA samples from 77 melanoma patients participating in a study investigating response to immunotherapy. Selected cases also have RNA sequencing of the tumour.

PROVIDER: EGAD00001004869 | EGA |

REPOSITORIES: EGA

ACCESS DATA

Json Xml

Publications

Whole-genome landscapes of major melanoma subtypes.

Hayward Nicholas K NK Wilmott James S JS Waddell Nicola N Johansson Peter A PA Field Matthew A MA Nones Katia K Patch Ann-Marie AM Kakavand Hojabr H Alexandrov Ludmil B LB Burke Hazel H Jakrot Valerie V Kazakoff Stephen S Holmes Oliver O Leonard Conrad C Sabarinathan Radhakrishnan R Mularoni Loris L Wood Scott S Xu Qinying Q Waddell Nick N Tembe Varsha V Pupo Gulietta M GM De Paoli-Iseppi Ricardo R Vilain Ricardo E RE Shang Ping P Lau Loretta M S LMS Dagg Rebecca A RA Schramm Sarah-Jane SJ Pritchard Antonia A Dutton-Regester Ken K Newell Felicity F Fitzgerald Anna A Shang Catherine A CA Grimmond Sean M SM Pickett Hilda A HA Yang Jean Y JY Stretch Jonathan R JR Behren Andreas A Kefford Richard F RF Hersey Peter P Long Georgina V GV Cebon Jonathan J Shackleton Mark M Spillane Andrew J AJ Saw Robyn P M RPM López-Bigas Núria N Pearson John V JV Thompson John F JF Scolyer Richard A RA Mann Graham J GJ

Nature 20170503 7653

Melanoma of the skin is a common cancer only in Europeans, whereas it arises in internal body surfaces (mucosal sites) and on the hands and feet (acral sites) in people throughout the world. Here we report analysis of whole-genome sequences from cutaneous, acral and mucosal subtypes of melanoma. The heavily mutated landscape of coding and non-coding mutations in cutaneous melanoma resolved novel signatures of mutagenesis attributable to ultraviolet radiation. However, acral and mucosal melanomas ...[more]

PMID: 28467829

Similar Datasets

Single-cell RNA-seq of tumor-infiltrating lymphocytes in metastatic uveal melanoma

Project description:Metastatic uveal melanoma generally responds poorly to immunotherapy. The aim here was to sequence tumor-infiltrating lymphocytes from uveal melanoma metastases to study their phenotypes and T-cell receptor (TCR) clonotypes. We performed paired single-cell transcriptome and TCR sequencing using the 10x Genomics platform of IL2-expanded tumor-infiltrating lymphocytes from 7 liver and 1 subcutaneous metastasis.

2020-03-16 | E-MTAB-8846 | biostudies-arrayexpress

Nanostring-Based Gene Expression Profiling of Melanoma Lymph Node Metastases

Project description:This study investigates gene expression profiles in metastatic melanoma lymph node samples using the Nanostring nCounter platform. Samples were obtained from patients who were treatment-naïve, resistant, or responsive to immune checkpoint inhibitor (ICI) therapy. We applied both the PanCancer Immune Profiling Panel and a custom tissue-resident memory (TRM) T cell panel to assess immune cell composition and activation states. The dataset reveals transcriptional signatures associated with ICI response, including enrichment of TRM-associated genes and interferon-stimulated pathways in responders, and immunosuppressive features in resistant tumors. These data provide insights into the role of tumour-resident T cells and the tumour immune microenvironment in shaping response to immunotherapy.

2026-06-08 | GSE294441 | GEO

Multi-model preclinical platform predicts clinical response of melanoma to immunotherapy

Project description:Multi-model preclinical platform predicts clinical response of melanoma to immunotherapy

| PRJNA605423 | ENA

Intra- and inter-tumoral heterogeneity of liver metastases in a patient with uveal melanoma

Project description:Tumour heterogeneity has been the main obstacle to the clinical efficacy of targeted and immunotherapy in cancer. An accurate understanding and recognition of tumour heterogeneity is critical in the clinical management of cancer patients. Here, we utilised single-cell RNA sequencing (scRNA-seq) to uncover the intra- and inter-tumoural heterogeneity of liver metastases from a patient with metastatic uveal melanoma.

2021-09-12 | GSE176029 | GEO

Bulk RNA-seq validation experiments for \High dimensional single cell analysis predicts response to anti-PD-1 immunotherapy\

Project description:Immune checkpoint blockade has revolutionized cancer therapy. In particular, inhibition of programmed cell death protein 1 (PD-1) is effective for the treatment of metastatic melanoma and other cancers. Despite a dramatic increase in progression-free survival, a large proportion of patients do not show durable response. Therefore, predictive biomarkers of clinical response are urgently needed. Here, we employed high-dimensional single cell mass cytometry and a bioinformatics pipeline for the in-depth characterization of the immune cell subsets in the peripheral blood of metastatic melanoma patients before and after anti-PD-1 immunotherapy. During therapy, we observed a clear treatment response to immunotherapy in the T cell compartment. However, prior to commending therapy a strong predictor of progression free and overall survival in response to anti-PD-1 immunotherapy was the frequency of CD14+CD16-HLA-DRhi monocytes. We could confirm this by conventional flow cytometry in an independent validation cohort and propose this as a novel predictive biomarker for therapy decisions in the clinic. In order to determine whether there are cell intrinsic changes in the monocyte signature, we performed RNA sequencing on sorted CD14+CD16-HLA-DRhi cells from HD, NR and R at baseline. Representative samples (n=4, each) of responders/non responders/ and healthy donors were selected from archival samples stored in the dermatology biobank according to the same clinical criteria used in the discovery and validation cohorts for CyTOF and FACS analysis. CD14+CD16-HLA-DRhiLin- (CD3, CD4, CD19, CD45RO) monocytes were sorted from frozen PBMC form blood samples from HD, R and NR at baseline.

2017-12-20 | E-MTAB-6214 | biostudies-arrayexpress

Screening of lncRNAs involved in cancer cell evasion of extrinsic and intrinsic apoptotic pathways

Project description:We generated ME4405 TRAIL-selected (TRAIL.S) and ME4405 UMI-77-selected (UMI-77.S) cell sub-lines that were resistant to TRAIL and the Mcl-1 inhibitor UMI-77, respectively, after long-term exposure to drug treatment. By performing RNA-sequencing analysis, we found that 37 upregulated lncRNAs in common between TRAIL.S and UMI-77.S cells, suggesting these lncRNAs may function in both extrinsic and intrinsic apoptotic pathways.

2018-09-13 | GSE119868 | GEO

Single-Cell and Spatial Transcriptome Analyses Reveal Tertiary Lymphoid Structures Linked to Tumour Progression and Immunotherapy Response in Nasopharyngeal Carcinoma

Project description:Tertiary lymphoid structures are immune cell aggregates linked with cancer outcomes, but their interactions with tumour cell aggregates are unclear. Using nasopharyngeal carcinoma as a model, we analyse single-cell transcriptomes of 343,829 cells from 77 biopsy and blood samples and spatially-resolved transcriptomes of 31,316 spots from 15 tumours to decipher their components and interactions with tumour cell aggregates. We identify essential cell populations in tertiary lymphoid structure, including CXCL13+ cancer-associated fibroblasts, stem-like CXCL13+CD8+ T cells, and B and T follicular helper cells. Our study shows that germinal centre reaction matures plasma cells. These plasma cells intersperse with tumour cell aggregates, promoting apoptosis of EBV-related malignant cells and enhancing immunotherapy response. CXCL13+ cancer-associated fibroblasts promote B cell adhesion and antibody production, activating CXCL13+CD8+ T cells that become exhausted in tumour cell aggregates. Tertiary lymphoid structure-related cell signatures correlate with prognosis and PD-1 blockade response, offering insights for therapeutic strategies in cancers.

2024-09-11 | GSE206245 | GEO

Single-cell RNA-sequencing of myeloid cells in E0771 breast tumours from CD1d-KO and WT mice

Project description:Myeloid cells play crucial roles in cancer progression, influencing tumour growth, metastasis, and response to immunotherapy. Tumour-infiltrating myeloid cells are highly heterogeneous, with functions ranging from anti-tumour to tumour-promoting. The mechanisms shaping these populations remain poorly understood and may offer therapeutic opportunities. Here, we identified the lipid-presenting molecule CD1d as a regulator of tumour progression and myeloid heterogeneity in the tumour microenvironment. CD1d-deficient mice exhibit reduced tumour growth and altered immune-infiltrates in breast cancer models. Similarly, targeting CD1d with an antibody, suppresses tumour growth, reshapes the myeloid landscape, and improves anti-PD-1 immunotherapy efficacy. The CD1d-dependent control of myeloid cell functional differentiation is cell-intrinsic and conserved in human and mouse. Single-cell RNA-sequencing revealed an enhanced proinflammatory program and accumulation of inflammatory monocytes in tumours from CD1d-KO animals. Subsequently, we generated a CD1d-KO-associated gene signature that predicts clinical outcomes and response to immunotherapy in breast cancer patients. Thus, CD1d could be targeted to alter tumour-infiltrating myeloid populations and enhance immunotherapy responses.

2026-07-16 | GSE317860 | GEO

Interleukin-4 modulates type I interferon to augment anti-tumour immunity [scRNA-Seq]

Project description:Despite advances in immunotherapy, metastatic melanoma remains a significant therapeutic challenge due to the complexity of the tumour microenvironment. Intratumoural type I interferon (IFN-I) has long been associated with improved clinical outcomes. However, several IFN-I subtypes can also paradoxically promote tumour growth in some contexts. We investigated this further by engineering murine B16 melanoma cells to overexpress various IFN-I subtypes, where a spectrum of outcomes was observed. Characterisation of these tumours by RNA-sequencing revealed a tumour immune phenotype, where potent IFN-I signalling concomitant with diminished type 2 inflammation failed to confer durable tumour control. T cell-mediated rejection of these tumours was restored by introducing interleukin (IL)-4 into the tumour microenvironment, either through ectopic expression or in a pre-clinical adoptive T cell therapy model. Collectively, our findings highlight the IFN-I/IL-4 axis in promoting anti-tumour immunity, which could be harnessed to target and stratify solid tumours that are non-responsive to frontline therapies.

2025-02-18 | GSE289723 | GEO

Interleukin-4 modulates type I interferon to augment anti-tumour immunity

2025-02-18 | GSE289722 | GEO